Replies to post #10401 on Biotech Values

[DewDiligence]

>>The costs of the US pIII will increase the burn (though it's a very small trial) and the Elan revenues will drop<<

The 27.8/4.5 calculation is based on the company’s own burn projection for the next three quarters, which includes expenses for the U.S. trial and excludes revenues from ELN. Hence, I do not understand your disagreement.